AMRX vs VRTX · P/E 44, rev $2.79B vs P/E 30, rev $12.00B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the AMRX and VRTX stock pages for the full models.
Not investment advice.